Innate Pharma SA Share Price Today: Live Updates & Key Insights

Innate Pharma SA share price today is $1.1736, up -7.87%. The stock opened at $1.3 against the previous close of $1.27, with an intraday high of $1.3 and low of $1.17.

Innate Pharma SA Share Price Chart

Innate Pharma SA

us-stock
To Invest in {{usstockname}}
us-stock

Innate Pharma SA Share Price Performance

$1.1736 -0.0787(-7.87%) IPHA at 23 Mar 2026 01:41 PM Biotechnology
Lowest Today 1.17
Highest Today 1.3
Today’s Open 1.3
Prev. Close 1.27
52 Week High 2.63
52 Week Low 1.17
Day’s Range: Low 1.17 High 1.3
52-Week Range: Low 1.17 High 2.63
1 day return -
1 Week return -10.44
1 month return -29.41
3 month return -31.81
6 month return -35.13
1 year return -38.14
3 year return -56.2
5 year return -72.66
10 year return -

Innate Pharma SA Institutional Holdings

Telescope Biotech Fund A FIL 0.10

Jane Street Group LLC 0.10

Morgan Stanley - Brokerage Accounts 0.06

OLD MISSION CAPITAL LLC. 0.03

Millennium Management LLC 0.02

Rhumbline Advisers 0.01

UBS Group AG 0.01

GAMMA Investing LLC 0.00

Barclays PLC 0.00

Citadel Advisors Llc 0.00

Optiver Holding B.V. 0.00

Principal Securities Inc 0.00

Innate Pharma SA Market Status

Strong Buy: 1

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Innate Pharma SA Fundamentals

Market Cap 110.60 M

PB Ratio 20.0588

PE Ratio 0.0

Enterprise Value 86.19 M

Total Assets 111.06 M

Volume 44972

Innate Pharma SA Company Financials

Annual Revenue FY23:51901000 51.9M, FY22:49639000 49.6M, FY21:12112000 12.1M, FY20:56833000 56.8M, FY19:68973000 69.0M

Annual Profit FY23:-4121000 -4.1M, FY22:49639000 49.6M, FY21:12112000 12.1M, FY20:53791000 53.8M, FY19:23815000 23.8M

Annual Net worth FY23:-7570000 -7.6M, FY22:-99103000 -99.1M, FY21:-59136000 -59.1M, FY20:-70747000 -70.7M, FY19:-20965000 -21.0M

Quarterly Revenue Q2/2025:4860000 4.9M, Q1/2025:276000 0.3M, Q2/2024:12345000 12.3M, Q1/2024:6172500 6.2M, Q4/2023:16556999 16.6M

Quarterly Profit Q2/2025:-15660000 -15.7M, Q1/2025:29352000 29.4M, Q2/2024:-16731000 -16.7M, Q1/2024:-8365500 -8.4M, Q4/2023:16556999 16.6M

Quarterly Net worth Q2/2025:-21344000 -21.3M, Q1/2025:-24707000 -24.7M, Q2/2024:-24764000 -24.8M, Q1/2024:-12382000 -12.4M, Q4/2023:-9288000 -9.3M

About Innate Pharma SA & investment objective

Company Information Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Organisation Biotechnology

Employees 174

Industry Biotechnology

CEO Mr. Jonathan E. Dickinson B.Sc., M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Innate Pharma SA FAQs

What is the share price of Innate Pharma SA today?

The current share price of Innate Pharma SA is $1.1736.

Can I buy Innate Pharma SA shares in India?

Yes, Indian investors can buy Innate Pharma SA shares by opening an international trading and demat account with Motilal Oswal.

How to buy Innate Pharma SA shares in India?

You can easily invest in Innate Pharma SA shares from India by:

Can I buy fractional shares of Innate Pharma SA?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Innate Pharma SA?

Innate Pharma SA has a market cap of $110.60 M.

In which sector does Innate Pharma SA belong?

Innate Pharma SA operates in the Biotechnology sector.

What documents are required to invest in Innate Pharma SA stocks?

To invest, you typically need:

What is the PE and PB ratio of Innate Pharma SA?

The PE ratio of Innate Pharma SA is N/A and the PB ratio is 20.06.